Analysis of Cell Type-Specific Responses Mediated by the Type IV Secretion System of Helicobacter pylori

Bianca Bauer; Stefan Moese; Sina Bartfeld; Thomas F. Meyer; Matthias Selbach

首页> 外文期刊>Infection and immunity >Analysis of Cell Type-Specific Responses Mediated by the Type IV Secretion System of Helicobacter pylori

【24h】

Analysis of Cell Type-Specific Responses Mediated by the Type IV Secretion System of Helicobacter pylori

机译：幽门螺杆菌IV型分泌系统介导的细胞类型特异性反应的分析

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Helicobacter pylori persistently infects the human stomach and can cause gastritis, gastric ulceration, and gastric cancer. The type IV secretion system (TFSS) of virulent H. pylori strains translocates the CagA protein, inducing the dephosphorylation of host cell proteins and leading to changes in the morphology or shape of AGS gastric epithelial cells. Furthermore, the TFSS is involved in the induction of proinflammatory cytokines. While the H. pylori genes required for TFSS function have been investigated systematically, little is known about possible host cell factors involved. We infected 19 different mammalian cell lines individually with H. pylori and analyzed CagA translocation, dephosphorylation of host cell proteins, chemokine secretion (interleukin-8 and macrophage inflammatory protein 2), and changes in cellular phenotypes. Our results demonstrate that not only bacterial but also host cell factors determine the cellular response to infection. The identification of such unknown host cell factors will add to our understanding of host-pathogen interactions and might help in the development of new therapeutic strategies.

机译：幽门螺杆菌持续感染人的胃，可引起胃炎，胃溃疡和胃癌。毒性H型病毒的IV型分泌系统（TFSS）。幽门螺杆菌菌株使CagA蛋白移位，诱导宿主细胞蛋白去磷酸化，并导致AGS胃上皮细胞的形态或形状发生变化。此外，TFSS参与促炎细胞因子的诱导。而 H。 TFSS功能所需的幽门螺杆菌基因已经过系统的研究，对可能涉及的宿主细胞因子知之甚少。我们分别用 H感染了19种不同的哺乳动物细胞系。并分析了CagA的转运，宿主细胞蛋白的去磷酸化，趋化因子分泌（白介素8和巨噬细胞炎性蛋白2）以及细胞表型的变化。我们的结果表明，不仅细菌因素而且宿主细胞因素都决定了细胞对感染的反应。这种未知宿主细胞因子的鉴定将增加我们对宿主-病原体相互作用的了解，并可能有助于开发新的治疗策略。 展开▼

著录项

来源
《Infection and immunity》 |2005年第8期|共10页

作者
Bianca Bauer; Stefan Moese; Sina Bartfeld; Thomas F. Meyer; Matthias Selbach;
展开▼

作者单位

展开▼

收录信息

原文格式 PDF

正文语种

中图分类医学免疫学;

关键词

相似文献

外文文献

中文文献

专利

1. Analysis of Cell Type-Specific Responses Mediated by the Type IV Secretion System of Helicobacter pylori [J] . Bianca Bauer, Stefan Moese, Sina Bartfeld, Infection and immunity . 2005,第8期

机译：幽门螺杆菌IV型分泌系统介导的细胞类型特异性反应的分析

2. Helicobacter pylori Type IV Secretion System and Its Adhesin Subunit, CagL, Mediate Potent Inflammatory Responses in Primary Human Endothelial Cells [J] . Tafreshi Mona, Guan Jyeswei, Gorrell Rebecca J., Frontiers in Cellular and Infection Microbiology . 2018,第2012期

机译：幽门螺杆菌IV型分泌系统及其粘附素亚基CagL介导人类原代内皮细胞的强效炎症反应。

3. Response to ‘Helicobacter pylori infection of AZ-521 cells reveals a type IV secretion defect and VacA-independent CagA phosphorylation’ [J] . Masayuki Nakano, Toshiya Hirayama Disease models & mechanisms: DMM . 2017,第12期

机译：对“幽门螺杆菌感染AZ-521细胞的反应表明IV型分泌缺陷和不依赖VacA的CagA磷酸化”

4. Identification of Helicobacter pylori proteins involved in the cag Type-IV secretion system apparatus via discovery and targeted mass spectrometry approaches [C] . Carrie L. Shaffer, W. Hayes McDonald, Salisha Hill, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：通过发现和靶向质谱方法鉴定CAG型-IV分泌系统装置中涉及的幽门螺杆菌蛋白

5. Characterization of the cag type IV secretion system and unique filaments of Helicobacter pylori [D] . Couturier, Marc Roger 2008

机译：IV型cag分泌系统的特征和幽门螺杆菌的独特细丝

6. Analysis of Cell Type-Specific Responses Mediated by the Type IV Secretion System of Helicobacter pylori [O] . Bianca Bauer, Stefan Moese, Sina Bartfeld, 2005

机译：幽门螺杆菌IV型分泌系统介导的细胞类型特异性反应的分析

7. Analysis of Cell Type-Specific Responses Mediated by the Type IV Secretion System of Helicobacter pylori [O] . Bauer, Bianca, Moese, Stefan, Bartfeld, Sina, 2005

机译：幽门螺杆菌IV型分泌系统介导的细胞类型特异性反应的分析

1. 幽门螺杆菌IV型分泌系统cagX基因缺失株的构建与鉴定 [J] . 高小焕 ,邵世和 ,段秀杰 . 江苏大学学报（医学版） . 2011,第002期

2. 幽门螺杆菌Ⅳ型分泌系统cagT基因的克隆表达及其重组蛋白对SGC-7901细胞增殖和分泌细胞因子功能的影响 [J] . 崔蕾蕾 ,邵世和 ,李良菊 . 微生物学报 . 2008,第004期

3. miR-142-5p靶向调控叉头转录蛋白O亚族3介导辅助性T细胞17细胞炎性反应促进自身免疫性葡萄膜炎的发展 [J] . 李媛 ,秦廷玉 ,郭龙 . 中华眼底病杂志 . 2021,第007期

4. AMP-活化蛋白激酶对氧葡萄糖剥夺复氧PC12细胞HMGB1释放及其介导的BY2细胞炎性反应的影响 [J] . 党辉 ,陆明佳 ,李红燕 . 国际脑血管病杂志 . 2016,第006期

5. MMP2/MMP9介导的CD100剪切在促进肝内HBV特异性CD8 T淋巴细胞应答和介导病毒的肝内清除中发挥关键作用 [J] . 李海军 . 临床肝胆病杂志 . 2019,第007期

6. 不同类型乙型肝炎病毒感染者抗原特异性T细胞免疫应答特征分析 [C] . 冯霞 ,王爽 ,王熠 . 第6届全国疑难及重症肝病大会 . 2011

7. 农杆菌介导的油菜遗传转化及花粉特异表达细胞周期基因分析 [A] . 文琴 . 2009

1. 人CD34阴性祖细胞保护血管内皮细胞层避免免疫介导的细胞毒性反应 [P] . 中国专利： CN105025927B . 2018.04.24

2. 人CD34阴性祖细胞保护血管内皮细胞层避免免疫介导的细胞毒性反应 [P] . 中国专利： CN105025927A . 2015-11-04

3. Vaccine composition, use of a helicobacter pylori polypeptide flge or a modified form thereof, use of the same, vaccine composition to induce a protective immune response to helicobacter pylori infection, in vitro diagnostic process of helicobacter pylori infection, kit method for detecting helicobacter pylori infection in a mammal including man, and process for eliciting a protective immune response against helicobacter pylori infection in a mammal [P] . 外国专利： BR9810026A . 2000-09-19

机译：疫苗组合物，幽门螺杆菌多肽壁或其修饰形式的用途，其用途，疫苗组合物诱导对幽门螺杆菌感染的保护性免疫应答，幽门螺杆菌感染的体外诊断方法，用于检测幽门螺杆菌感染的试剂盒方法包括人在内的哺乳动物中的表达，以及引起针对幽门螺杆菌感染的保护性免疫应答的方法

4. Compound, process for the preparation of it, pharmaceutical formulation, use of the compound, processes to inhibit gastric acid secretion, for the treatment of inflammatory gastrointestinal diseases, and for the treatment or prophylaxis of conditions involving helicobacter pylori infection of the mucosa human gastric, and, pharmaceutical formulations for use in inhibiting gastric acid secretion, for use in the treatment of inflammatory gastrointestinal diseases, and for use in the treatment or prophylaxis of conditions involving helicobacter pylori infection of the human gastric mucosa [P] . 外国专利： BR9913103A . 2001-05-08

机译：该化合物，其制备方法，药物制剂，该化合物的使用，抑制胃酸分泌的方法，用于治疗炎性胃肠疾病以及用于治疗或预防人胃黏膜幽门螺杆菌感染的疾病的方法，以及用于抑制胃酸分泌，用于治疗炎性胃肠疾病以及用于治疗或预防涉及人胃粘膜的幽门螺杆菌感染的疾病的药物制剂

5. composition, pharmaceutical composition, effervescent dosage form, multiple unit oral oral pharmaceutical composition, extended release pharmaceutical dosage form, enteric coated pharmaceutical dosage form, stable pharmaceutical dosage form for oral administration to mammalian subjects, method for treating diseases acid-related diseases by inhibiting gastric acid secretion, method for treating a bacterial infection caused or caused by helicobacter pylori, process for preparing a compound of formula 3, process for preparing a compound of formula 5, use of a compound of formula 1 for the preparation of a medicament for treating gastric acid-related diseases by inhibiting gastric acid secretion, use of a compound of formula 1 for the preparation of a medicament for treating a bacterial infection caused or caused by helicobacter pyl or use of a compound of formula 1 for the preparation of a medicament for treating gastric acid-related diseases by inhibiting gastric acid secretion [P] . 外国专利： BRPI0617987A2 . 2011-08-16

机译：组合物，药物组合物，泡腾剂型，多单位口服口服药物组合物，缓释药物剂型，肠溶衣药物剂型，向哺乳动物受试者口服给药的稳定药物剂型，通过抑制胃酸治疗疾病的方法酸分泌，治疗由幽门螺杆菌引起或引起的细菌感染的方法，制备式3化合物的方法，制备式5化合物的方法，式1化合物在制备用于治疗胃的药物中的用途通过抑制胃酸分泌来治疗与酸有关的疾病，将式1的化合物用于制备用于治疗由幽门螺杆菌引起或引起的细菌感染的药物，或将式1的化合物用于制备用于治疗的药物通过抑制胃酸分泌来治疗胃酸相关疾病

相关主题

Analysis of Cell Type-Specific Responses Mediated by the Type IV Secretion System of Helicobacter pylori

摘要

著录项

相似文献

相关主题

期刊订阅